Drug Discovery & DDS– category –
-
Elunetirom: Phase 2 AMPLIFY-BD trial results for bipolar depression
Pharmacally International Overview Elunetirom demonstrated favorable results in the Phase 2 AMPLIFY-BD open-label trial for bipolar depression, significantly reducing depressive symptoms and improving patient function. In 21 adults with ... -
LUNAR 2.0: Arcturus Therapeutics mRNA expression roadmap
Morningstar USA Overview Arcturus Therapeutics announced interim Phase 2 results for ARCT-810 in OTC Deficiency and unveiled its next-generation mRNA delivery platform, LUNAR 2.0™. ARCT-810 demonstrated a favorable safety profile and pro... -
mRNA Vaccine LNP: South Korea’s 2026 organ targeting specs
Vertex AI Search South Korea Overview In South Korea, new lipid nanoparticle (LNP) strategies for mRNA vaccines are being developed, including Selective Organ Targeting (SORT) to lung, spleen, and lymph nodes, and ligand conjugation to L... -
AI drug discovery: 80-90% Phase I success rate explained
World Health Expo International Overview AI-identified drug candidates have demonstrated an impressive 80-90% success rate in Phase I clinical trials, significantly surpassing the historical industry average. This breakthrough is driven ... -
Orforglipron: Eli Lilly oral GLP-1 vs injectable efficacy
Apps Script USA Overview Eli Lilly's investigational oral GLP-1 receptor agonist, Orforglipron, has shown potent weight loss and glycemic control effects in early clinical trials comparable to injectable GLP-1 drugs for type 2 diabetes a... -
Oral GLP-1 drugs: 2026 clinical trial bioavailability specs
Vertex AI Search (grounding-api-redirect) USA Overview New oral GLP-1 medications in clinical trials have significantly improved bioavailability through the use of novel absorption enhancers, overcoming traditional degradation challenges... -
Drug Discovery & DDS Weekly Report September 20, 2026
▼ ▼ ▼ If the infographic makes you want to read the full report, please click the download button below. ▼ ▼ ▼ 📄 Weekly Report September 20, 2026 (PDF) — Download Weekly Report September 20, 2026 (PDF) — DownloadDownload 🎙 Podcast Septe... -
Arbutus & Genevant Sue Federal Government for Patent Infringement on Moderna mRNA Vaccine LNP Components
Patent Docs United States Overview On September 11, 2026, Arbutus Biopharma and Genevant Sciences filed a patent infringement lawsuit against the U.S. Federal Government regarding the lipid nanoparticle (LNP) components used in Moderna’s... -
Korsana Biosciences Secures $380 Million in PIPE Financing to Advance Alzheimer’s Disease Pipeline
Panabee (Korsana Biosciences) United States Overview On September 10, 2026, Korsana Biosciences successfully completed a $380 million PIPE (Private Investment in Public Equity) financing to accelerate its Alzheimer's disease (AD) therape... -
Samsung Biologics Secures $262M Manufacturing Contract with European Pharma Amid Peptide Expansion and CDMO Capacity Growth
BioProcess International South Korea Overview On September 10, 2026, Samsung Biologics announced a $262 million manufacturing agreement with an undisclosed European pharmaceutical company. This substantial contract will further accelerat...
